Pages that link to "Q43036959"
Jump to navigation
Jump to search
The following pages link to SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders (Q43036959):
Displaying 50 items.
- Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C (Q24201588) (← links)
- Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors (Q24645702) (← links)
- In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor (Q24650264) (← links)
- Emerging therapeutic options for the management of hepatitis C infection (Q27012744) (← links)
- Viral Determinants of Resistance to Treatment in Patients with Hepatitis C (Q27478062) (← links)
- Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease (Q27485288) (← links)
- Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System (Q27485441) (← links)
- The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors (Q27485895) (← links)
- Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus (Q27486122) (← links)
- Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors (Q27486249) (← links)
- Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors (Q27486813) (← links)
- Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796 (Q27486816) (← links)
- Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479 (Q27487389) (← links)
- Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) (Q27487391) (← links)
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon (Q27487518) (← links)
- Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034) (Q27487769) (← links)
- Fluorescence Resonance Energy Transfer-Based Assay for Characterization of Hepatitis C Virus NS3-4A Protease Activity in Live Cells (Q27487770) (← links)
- Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected Individual (Q27488198) (← links)
- A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients (Q27488742) (← links)
- Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C (Q27488958) (← links)
- Proanthocyanidin from Blueberry Leaves Suppresses Expression of Subgenomic Hepatitis C Virus RNA (Q27489836) (← links)
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease (Q27490545) (← links)
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding (Q27665956) (← links)
- Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease (Q27667503) (← links)
- High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes (Q28534286) (← links)
- HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil (Q28538943) (← links)
- Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection (Q28729744) (← links)
- Boceprevir for untreated chronic HCV genotype 1 infection (Q29620617) (← links)
- Hepatitis C treatment: where are we now? (Q30378509) (← links)
- Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic. (Q30381336) (← links)
- Advances in the treatment of hepatitis C virus infection (Q30415138) (← links)
- Pharmacokinetics of new oral hepatitis C antiviral drugs (Q30422746) (← links)
- Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function (Q33455220) (← links)
- Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6 (Q33826766) (← links)
- Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling (Q33899320) (← links)
- Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study (Q33956796) (← links)
- The way forward in HCV treatment--finding the right path (Q34008483) (← links)
- Hepatitis C protease and polymerase inhibitors in development (Q34085348) (← links)
- Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease (Q34105938) (← links)
- New HCV therapies on the horizon (Q34150558) (← links)
- Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. (Q34206923) (← links)
- Hepatitis C virus experimental model systems and antiviral drug research (Q34235286) (← links)
- Antiviral treatment for hepatitis C virus infection after liver transplantation (Q34340293) (← links)
- Therapeutic implications of hepatitis C virus resistance to antiviral drugs (Q34409020) (← links)
- MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. (Q34411907) (← links)
- Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection (Q34506788) (← links)
- Rapid emergence of protease inhibitor resistance in hepatitis C virus (Q34551913) (← links)
- Direct-acting antivirals for chronic hepatitis C. (Q34557595) (← links)
- Potential treatment options and future research to increase hepatitis C virus treatment response rate (Q34576190) (← links)
- The flavivirus protease as a target for drug discovery (Q34657530) (← links)